U.S. Markets closed

NewLink Genetics price target raised to $23 from $20 at RW Baird

Baird raised its price target on NewLink Genetics as they continue to see a positive risk/reward scenario. The firm expects key events such as Phase 3 interim data for IMPRESS as a catalyst and views yesterday's dip as a buying opportunity. Shares are Outperform rated.